Insider Selling: Fennec Pharmaceuticals Inc. (TSE:FRX) Director Sells 2,431 Shares of Stock

Fennec Pharmaceuticals Inc. (TSE:FRX) Director Rostislav Christov Raykov sold 2,431 shares of the company’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of C$6.13, for a total value of C$14,902.03.

Fennec Pharmaceuticals Price Performance

FRX stock opened at C$8.16 on Thursday. The business’s fifty day moving average price is C$10.11 and its 200 day moving average price is C$12.47. Fennec Pharmaceuticals Inc. has a 12-month low of C$8.16 and a 12-month high of C$15.43. The company has a market capitalization of C$222.93 million, a PE ratio of 163.20 and a beta of 0.46. The company has a current ratio of 6.93, a quick ratio of 10.17 and a debt-to-equity ratio of 1,040.68.

Fennec Pharmaceuticals (TSE:FRX) last issued its quarterly earnings results on Tuesday, May 14th. The biopharmaceutical company reported C$0.56 earnings per share (EPS) for the quarter, missing the consensus estimate of C$0.67 by C($0.11). The business had revenue of C$34.21 million for the quarter, compared to analyst estimates of C$14.19 million. Fennec Pharmaceuticals had a negative return on equity of 1,005.59% and a net margin of 6.33%. On average, sell-side analysts anticipate that Fennec Pharmaceuticals Inc. will post 1.1958225 EPS for the current year.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.